These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 32592141)

  • 1. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
    Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
    Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
    Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
    Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
    Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
    Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer.
    Oshiro C; Yamasaki M; Noda Y; Nishimae A; Takahashi H; Inaji H
    Breast Cancer; 2020 Sep; 27(5):947-953. PubMed ID: 32297249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER
    Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.
    Hu J; Fung MW; Tsang JY; Poon IK; Chan SK; Cheung SY; Hu H; Zhou D; Tse GM
    Clin Breast Cancer; 2020 Jun; 20(3):253-261.e7. PubMed ID: 32205037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
    Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
    Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
    Kimbung S; Inasu M; Stålhammar T; Nodin B; Elebro K; Tryggvadottir H; Ygland Rödström M; Jirström K; Isaksson K; Jernström H; Borgquist S
    Breast Cancer Res; 2020 Nov; 22(1):123. PubMed ID: 33176848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
    Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
    [No Abstract]   [Full Text] [Related]  

  • 14. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
    Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution.
    Tokunaga E; Ijichi H; Tajiri W; Masuda T; Takizawa K; Ueo H; Koga C; Tanaka J; Nakamura Y; Ohno S; Taguchi K; Okamoto M
    Breast Cancer; 2020 Nov; 27(6):1137-1146. PubMed ID: 32472474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.
    Veitch Z; Khan OF; Tilley D; Ribnikar D; Kostaras X; King K; Tang P; Lupichuk S
    J Natl Compr Canc Netw; 2019 Jan; 17(1):47-56. PubMed ID: 30659129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.